ShenZhen GTJA Investment Group
VC Fund
Shenzhen, China
ShenZhen GTJA Investment Group is a VC fund in Shenzhen focused on Health Care and Biotechnology. ShenZhen GTJA Investment Group was founded in 2001
- Total investments:
- 70
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries ShenZhen GTJA Investment Group invests in
Stages ShenZhen GTJA Investment Group invests in
Countries ShenZhen GTJA Investment Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $1.4M–$60M
- Series B
- $3.1M–$130M
- Series C
- $4.3M–$130M
Investment Focus
Industry
- Health Care 21 (30%)
- Biotechnology 16 (23%)
- Pharmaceutical 13 (19%)
- Medical 12 (17%)
- Biopharma 8 (11%)
Stage
- Series B 14 (20%)
- Series A 7 (10%)
- Series C 7 (10%)
- Angel 6 (9%)
- Series D 4 (6%)
Country
- China 43 (61%)
- United States 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dajian Cai
Chairman
|
Chairman | Total investments: 1 | Find email | |
|
Haijiao Wang
Deputy General Manager
|
Deputy General Manager | Total investments: 3 | Find email | |
Sun Jialin
Executive Partner
|
Executive Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Xianyan Biopharma
|
Xianyan Biopharma is a company that focuses on core technology innovation and new medication development for oligonucleotides, and it has a top-tier R&D staff. | Series A / Aug 31, 2026 | |
Xgene Pharmaceutical
|
Xgene Pharmaceutical is a pharmaceutical company. | $36.9M / Series D / Jul 28, 2026 | |
Jindu Biotechnology
|
Jindu Biosciences is a global leader at the intersection of artificial intelligence and life sciences. The company is dedicated to advancing biological research by integrating cutting-edge AI technologies with bioinformatics and multi-omics data analysis. Their mission is to accelerate the life sciences field into a new era dominated by pre-trainedAI models, enabling faster, more accurate biological discoveries and innovations. | $14.8M / Series A / Jun 11, 2026 | |
Degron Therapeutics
|
Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment. | $40M / Series A / May 14, 2026 | |
Four Stars
|
Four Starsy focuses on the R&D, production, and sales of pharmaceutical glass packaging materials. | $44M / Venture - Series Unknown / Apr 27, 2026 | |
Infinity Neuro Technology
|
Suzhou Infinity Neuro Technology Co., Ltd. primarily engages in the research, development, production, and commercialization of advanced medical devices in the cerebrovascular field, focusing on innovative technologies that improve the diagnosis, treatment, and overall management of neurological and vascular disorders. | Series A / Dec 09, 2025 | |
BridGene Biosciences
|
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets. | $28M / Series B / Oct 16, 2025 | |
Chenglian Technology
|
Chamlion 3D is a national high-tech enterprise incubated and established by the Additive Manufacturing Institute of Nanjing University of Aeronautics and Astronautics. Digital solutions for dental 3D printing, leading the digital transformation and upgrading of the industry. Chenglian Technology is deeply engaged in the field of dentistry, with itsin-depth understanding of the industry and rich product development. | $27.8M / Series B / May 27, 2025 | |
Qingpai Technology
|
Qingpai Technology is a developer of photoacoustic biomedical imaging technology. It develops new clinical medical and high-end scientific research imaging platform products based on photoacoustic imaging technology, which can be used for early screening and diagnosis of breast cancer, pre-and post-operative skin flap transplantation evaluation,preoperative parathyroid detection and positioning imaging, male genital vascular imaging, skin medical cosmetology, and carotid artery plaque detection imaging. | Seed / Feb 06, 2025 | |
Rosenbot
|
Rosenbot provides medical robot technology and uses technological innovation to promote the reform of medical models. It is committed to creating a new generation of orthopedic surgery robot systems with intelligent fracture reduction functions, it is the first in the world to realize advanced technologies such as intraoperative real-time 3Dnavigation, assisted fracture reduction operation, automatic operation planning, etc. The intelligent surgical operation of the whole operation process meets the urgent needs of clinical treatment. | Series C / Jan 20, 2025 | |
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ShenZhen GTJA Investment Group invest in?
ShenZhen GTJA Investment Group invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 70 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ShenZhen GTJA Investment Group's check size?
ShenZhen GTJA Investment Group typically joins rounds of $1.4M–$60M at Series A, $3.1M–$130M at Series B and $4.3M–$130M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ShenZhen GTJA Investment Group participates in.
How do I contact ShenZhen GTJA Investment Group?
Public channels for ShenZhen GTJA Investment Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ShenZhen GTJA Investment Group?
The team at ShenZhen GTJA Investment Group includes Dajian Cai (Chairman), Haijiao Wang (Deputy General Manager) and Sun Jialin (Executive Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
